Literature DB >> 27634580

Fingolimod enhances myelin repair of hippocampus in pentylenetetrazol-induced kindling model.

Mohammad Gol1, Davoud Ghorbanian1, Samaneh Hassanzadeh1, Mohammad Javan2, Javad Mirnajafi-Zadeh2, Maryam Ghasemi-Kasman3.   

Abstract

Recent evidence indicates that demyelination occurs in epilepsy patients and kindling animal models. Regarding the well-known literature on anti-inflammatory and myelin protective effects of fingolimod (FTY720) in multiple sclerosis patients and animal models, we hypostatized whether FTY720 administration could exert myelin protective effects in pentylenetetrazol (PTZ)-induced kindling model. To end this, animals received 0.3 or 1mg/kg dosage of FTY720, 1h before PTZ injections. In another approach, after achieving fully kindling stage, FTY720 was administrated i.p. once daily for 7 consecutive days. Treatment with FTY720 (especially lower dose) reduced the frequency of seizures and epileptiform discharges in both approaches. We found that FTY720 administration decreases cell death and glial activation in CA1 and CA3 regions of hippocampus. Myelin protection effect was shown by increasing myelin levels. Furthermore, post-treatment of FTY720 enhanced endogenous remyelination and the number of oligodendrocyte precursor cells in fully kindled animals. Together, these results demonstrate that FTY720 behind the anti-inflammatory and neuroprotection effects has beneficial role in myelin protection and remyelination enhancement in PTZ kindling model of seizure and it may be provide a new therapeutic option for demyelination associated with epilepsy.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Demyelination; Epilepsy; Fingolimod; Inflammation; Myelin protection; Neuroprotection

Mesh:

Substances:

Year:  2016        PMID: 27634580     DOI: 10.1016/j.ejps.2016.09.016

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  14 in total

1.  Fingolimod Exerts only Temporary Antiepileptogenic Effects but Longer-Lasting Positive Effects on Behavior in the WAG/Rij Rat Absence Epilepsy Model.

Authors:  Antonio Leo; Rita Citraro; Nicola Amodio; Caterina De Sarro; Maria Eugenia Gallo Cantafio; Andrew Constanti; Giovambattista De Sarro; Emilio Russo
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

2.  Anti-epileptogenic and Anti-convulsive Effects of Fingolimod in Experimental Temporal Lobe Epilepsy.

Authors:  Julika Pitsch; Julia C Kuehn; Vadym Gnatkovsky; Johannes Alexander Müller; Karen M J van Loo; Marco de Curtis; Hartmut Vatter; Susanne Schoch; Christian E Elger; Albert J Becker
Journal:  Mol Neurobiol       Date:  2018-06-22       Impact factor: 5.590

3.  Fingolimod Affects Transcription of Genes Encoding Enzymes of Ceramide Metabolism in Animal Model of Alzheimer's Disease.

Authors:  Henryk Jęśko; Przemysław L Wencel; Sylwia Wójtowicz; Joanna Strosznajder; Walter J Lukiw; Robert P Strosznajder
Journal:  Mol Neurobiol       Date:  2020-04-30       Impact factor: 5.590

4.  Co-administration of aspirin and adipose-derived stem cell conditioned medium improves the functional recovery of the optic pathway in a lysolecithin-induced demyelination model.

Authors:  Adel Galeshi; Maryam Ghasemi-Kasman; Farideh Feizi; Nahid Davoodian; Leila Zare; Zeinab Abedian
Journal:  Neuropsychiatr Dis Treat       Date:  2019-09-17       Impact factor: 2.570

Review 5.  From the Molecular Mechanism to Pre-clinical Results: Anti-epileptic Effects of Fingolimod.

Authors:  Yam Nath Paudel; Efthalia Angelopoulou; Christina Piperi; Vadym Gnatkovsky; Iekhsan Othman; Mohd Farooq Shaikh
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

6.  Reversing Alzheimer's disease dementia with clemastine, fingolimod, or rolipram, plus anti-amyloid therapy.

Authors:  Jeffrey Fessel
Journal:  Alzheimers Dement (N Y)       Date:  2022-02-01

7.  Immunomodulation Eliminates Inflammation in the Hippocampus in Experimental Autoimmune Encephalomyelitis, but Does Not Ameliorate Anxiety-Like Behavior.

Authors:  Pece Kocovski; Nuzhat Tabassum-Sheikh; Stephanie Marinis; Phuc T Dang; Matthew W Hale; Jacqueline M Orian
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

Review 8.  Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System.

Authors:  Kim M A De Kleijn; Gerard J M Martens
Journal:  Int J Mol Sci       Date:  2020-06-13       Impact factor: 5.923

9.  Fabrication and evaluation of novel quercetin-conjugated Fe3O4-β-cyclodextrin nanoparticles for potential use in epilepsy disorder.

Authors:  Mona Hashemian; Maryam Ghasemi-Kasman; Shahram Ghasemi; Atefeh Akbari; Monire Moalem-Banhangi; Leila Zare; Seyed Raheleh Ahmadian
Journal:  Int J Nanomedicine       Date:  2019-08-13

Review 10.  Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis.

Authors:  Pablo Bascuñana; Luisa Möhle; Mirjam Brackhan; Jens Pahnke
Journal:  Drugs R D       Date:  2020-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.